Small-molecule inhibitors of spleen tyrosine kinase as therapeutic agents for immune disorders: Will promise meet expectations?

Future Medicinal Chemistry

Volumn 6, Issue 16, 2014, Pages 1811-1827

  Lucas, Matthew C ^a   Tan, Seng Lai ^b  

^a CUBIST PHARMACEUTICALS INC   (United States)

^b EMD Serono Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOSTAMATINIB; IDELALISIB; IMMUNOSUPPRESSIVE AGENT; NETUPITANT; PROTEIN KINASE SYK INHIBITOR; MOLECULAR LIBRARY; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ALLERGIC RHINITIS; ANTIGEN RECOGNITION; ASTHMA; AUTOIMMUNE DISEASE; CONFORMATIONAL TRANSITION; FINANCIAL MANAGEMENT; HIGH THROUGHPUT SCREENING; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE ILEUS; PROTEIN CONFORMATION; PROTEIN INTERACTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; X RAY CRYSTALLOGRAPHY; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; IMMUNE SYSTEM DISEASES; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; SPLEEN;

HUMANS; IMMUNE SYSTEM DISEASES; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SMALL MOLECULE LIBRARIES; SPLEEN;

EID: 84911905453     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.126     Document Type: Review

References (72)

1. Cohen P, Alessi DR. Kinase drug discovery-what's next in the field? ACS Chem. Biol. 8(1), 96-104 (2013
2. Cohen P. Targeting protein kinases for the development of anti-inflammatory drugs. Curr. Opin. Cell Biol. 21(2), 317-322 (2009
3. Westhovens R, Keyser FD, Rekalov D, et al. Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a Phase II, randomised, double-blind, placebo-controlled, multicentre trial. Ann. Rheum. Dis. 72(5), 741-744 (2013
4. Paniagua RT, Sharpe O, Ho PP, et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J. Clin. Invest. 116(10), 2633-2642 (2006
5. MedImmune, Pipeline. www.medimmune.com/research/pipeline
6. Forbes, Immunokinase Drug Candidates. 12B in Value Creation and Counting. www.forbes.com/sites/brucebooth/2013/03/13/immunokinasedrug-candidates-12b-in-value-creation-And-counting
7. Mócsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat. Rev. Immunol. 10(6), 387-402 (2010
8. Riccaboni M, Bianchi I, Petrillo P. Spleen tyrosine kinases: biology, therapeutic targets and drugs. Drug Discov. Today 15(13-14), 517-530 (2010
9. Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol. Rev. 237(1), 264-283 (2010
10. Nimmerjahn F. Activating and inhibitory FcgammaRs in autoimmune disorders. Springer Semin. Immunopathol. 28(4), 305-319 (2006
11. Tan S-L, Liao C, Lucas MC, Stevenson C, DeMartino JA. Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives. Pharmacol. Ther. 138(2), 294-309 (2013
12. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N. Engl. J. Med. 363(14), 1303-1312 (2010
13. Nijjar JS, Tindell A, McInnes IB, Siebert S. Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis. Rheumatology 52(9), 1556-1562 (2013
14. Davis MI, Hunt JP, Herrgard S, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 29(11), 1046-1051 (2011
15. Meltzer EO, Berkowitz RB, Grossbard EB. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J. Allergy Clin. Immunol. 115(4), 791-796 (2005
16. Moy LY, Jia Y, Caniga M, et al. Inhibition of spleen tyrosine kinase attenuates allergen-mediated airway constriction. Am. J. Respir. Cell. Mol. Biol. 49(6), 1085-1092 (2013
17. Penton PC, Wang X, Amatullah H, et al. Spleen tyrosine kinase inhibition attenuates airway hyperresponsiveness and pollution-induced enhanced airway response in a chronic mouse model of asthma. J. Allergy Clin. Immunol. 131(2), 512-520, e1-e10 (2013
18. Huang ZY, Kim MK, Kim-Han TH, Indik ZK, Schreiber AD. Effect of locally administered Syk siRNA on allergen-induced arthritis and asthma. Mol. Immunol. 53(1-2), 52-59 (2013
19. Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 113(14), 3154-3160 (2009
20. Rigel. www.rigel.com
21. Wyatt RJ, Julian BA. IgA nephropathy. N. Engl. J. Med. 368(25), 2402-2414 (2013
22. Kim MJ, McDaid JP, McAdoo SP, et al. Spleen tyrosine kinase is important in the production of proinflammatory cytokines and cell proliferation in human mesangial cells following stimulation with IgA1 isolated from IgA nephropathy patients. J. Immunol. 189(7), 3751-3758 (2012
23. Smith J, McDaid JP, Bhangal G, et al. A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis. J. Am. Soc. Nephrol. 21(2), 231-236 (2010
24. Isenberg DA, Rahman A. Systemic lupus erythematosus in 2013. Taking a closer look at biologic therapy for SLE. Nat. Rev. Rheumatol. 10(2), 71-77 (2014
25. Deng G-M, Liu L, Bahjat FR, Pine PR, Tsokos GC. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum. 62(7), 2086-2092 (2010
26. Bahjat FR, Pine PR, Reitsma A, et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum. 58(5), 1433-1444 (2008
27. Schweighoffer E, Vanes L, Nys J, et al. The BAFF receptor transduces survival signals by co-opting the B cell receptor signaling pathway. Immunity 38(3), 475-488 (2013
28. Konya C, Paz Z, Tsokos GC. The role of T cells in systemic lupus erythematosus: an update. Curr. Opin. Rheumatol. 26(5), 493-501 (2014
29. Krishnan S, Juang YT, Chowdhury B, et al. Differential expression and molecular associations of SYK in systemic lupus erythematosus T cells. J. Immunol. 181(11), 8145-8152 (2008
30. Grammatikos AP, Ghosh D, Devlin A, Kyttaris VC. Tsokos GC. Spleen tyrosine kinase (Syk) regulates systemic lupus erythematosus (SLE) T cell signaling. PLoS ONE 8(8), e74550 (2013
31. van Bree SH, Gomez-Pinilla PJ, van de Bovenkamp FS, et al. Inhibition of spleen tyrosine kinase as treatment of postoperative ileus. Gut 62(11), 1581-1590 (2013
32. Norman P. Spleen tyrosine kinase inhibitors: a review of the patent literature 2010-2013. Expert Opin. Ther. Pat. 24(5), 573-595 (2014
33. Moretto AF, Dehnhardt C, Kaila N, Papaioannou N, Thorarensen A. The 2010 patent landscape for spleen tyrosine kinase inhibitors. Recent Pat. Inflamm. Allergy Drug Discov. 6(2), 97-120 (2012
34. Moore WJ, Richard D, Thorarensen A. An analysis of the diaminopyrimidine patent estates describing spleen tyrosine kinase inhibitors by Rigel and Portola. Expert Opin. Ther. Pat. 20(12), 1703-1722 (2010
35. Lucas MC, Goldstein DM, Hermann JC, et al. Rational design of highly selective spleen tyrosine kinase inhibitors. J. Med. Chem. 55(23), 10414-10423 (2012
36. Currie KS, Kropf JE, Lee T, et al. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase. J. Med. Chem. 57(9), 3856-3873 (2014
37. Merck Sharp & Dohme Corp.: WO031438 (2014
38. Merck Sharp & Dohme Corp.: WO192125 (2013
39. Merck Sharp & Dohme Corp.: WO192128 (2013
40. Boehringer Ingelheim International GBBH: WO156608 (2013
41. Merck GMBH: WO023385 (2014
42. Merck GMBH: WO124026 (2013
43. Merck GMBH: WO124025 (2013
44. Merck GMBH: WO126132 (2013
45. Gilead Connecticut, Inc.: WO188856 (2013
46. Hoffmann-La Roche, Inc.: US0178460 (2013
47. Hoffmann-La Roche, Inc.: WO029732 (2014
48. Portola Pharmaceuticals, Inc.: US0345191 (2013
49. Novartis AG: WO027300 (2014
50. Novartis AG: WO171690 (2013
51. Singh R, Masuda ES, Payan DG. Discovery and development of spleen tyrosine kinase (SYK) inhibitors. J. Med. Chem. 55(8), 3614-3643 (2012
52. Skinner M, Philp K, Lengel D, et al. The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation. Br. J. Pharmacol. 171(9), 2308-2320 (2014
53. Hisamichi H, Naito R, Toyoshima A, et al. Synthetic studies on novel Syk inhibitors. Part 1: synthesis and structure-Activity relationships of pyrimidine-5-carboxamide derivatives. Bioorg. Med. Chem. 13(16), 4936-4951 (2005
54. Villaseñor AG, Kondru R, Ho H, et al. Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes. Chem. Biol. Drug Des. 73(4), 466-470 (2009
55. BIIB057 in subjects with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs (EMBRACE). http://clinicaltrials.gov/show/NCT01652937
56. Biogen Idec. www.biogenidec.com
57. Liddle J, Atkinson FL, Barker MD, et al. Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor. Bioorg. Med. Chem. Lett. 21(20), 6188-6194 (2011
58. Lucas MC, Bhagirath N, Chiao E, et al. Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors. J. Med. Chem. 57(6), 2683-2691 (2014
59. Liao C, Hsu J, Kim Y, et al. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy. Arthritis Res. Ther. 15(5), R146 (2013
60. Thoma G, Blanz J, Bühlmayer P, et al. Syk inhibitors with high potency in presence of blood. Bioorg. Med. Chem. Lett. 24(10), 2278-2282 (2014
61. Burgdorf L. A novel class of selective SYK inhibitors: pyridopyrimidines. Presented at: Cambridge Healthtech Institutes 9th Annual Drug Discovery Chemistry, San Diego, CA, USA, 23-25 April 2014
62. A Phase 2 of GS-9973 in subjects with relapsed or refractory hematologic malignancies. http://clinicaltrials.gov/show/NCT01799889
63. Fruman DA, Cantley LC. Idelalisib-A PI3Kdelta inhibitor for B-cell cancers. N. Engl. J. Med. 370(11), 1061-1062 (2014
64. A Phase 2 of GS-9973 in combination with idelalisib in subjects with relapsed or refractory hematologic malignancies. http://clinicaltrials.gov/show/NCT01796470
65. Hoffmann-La Roche, Inc.: WO144585 (2011
66. Hoffmann-La Roche, Inc.: US0230462 (2011
67. Hoffmann-La Roche, Inc.: US0215750 (2009
68. Hoffmann-La Roche, Inc.: US0215724 (2009
69. Padilla F, Bhagirath N, Chen S, et al. Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors. J. Med. Chem. 56(4), 1677-1692 (2013
70. Castillo M, Forns P, Erra M, et al. Highly potent aminopyridines as Syk kinase inhibitors. Bioorg. Med. Chem. Lett. 22(17), 5419-5423 (2012
71. Spurgeon SE, Coffey G, Fletcher LB, et al. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. J. Pharmacol. Exp. Ther. 344(2), 378-387 (2013
72. Zhao H, Caflisch A. Discovery of dual ZAP70 and Syk kinases inhibitors by docking into a rare C-helix-out conformation of Syk. Bioorg. Med. Chem. Lett. 24(6), 1523-1527 (2014